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INTRODUCTION: Recent studies have shown a 
high prevalence of S100 calcium-binding protein P 
(S100P) in pancreatic ductal adenocarcinoma 
(PDAC). S100P activates key cell signalling 
pathways including mitogen-activated protein 
(MAP) kinase and nuclear factor-B (NFκB) 
pathways through its extracellular interaction with 
the receptor for advanced glycation end products 
(RAGE) [1-2]. Interaction between the metastasis-
promoting protein S100P and RAGE has been 
shown to mediate pancreatic tumour proliferation, 
survival, invasion and metastasis progression [2]. 
This project aims to identify novel hit compounds 
that attach to and prevent S100P from binding to 
and activating RAGE to prevent cell proliferation 
and migration in human pancreatic cells. 
METHODS: Hit compounds predicted to bind 
S100P and inhibit its tumour-promoting effects 
were designed based on computational modelling of 
a small-molecule binding site in S100P in a virtual 
screen. An enzyme linked immunosorbent assay 
(ELISA), to detect S100P-RAGE binding, was 
developed based on a published protocol [2]; 18 of 
all 93 hit compounds (purchased or synthesised in-
house) which were screened for inhibition of 
S100P-RAGE interaction using this assay 
significantly inhibited S100P/RAGE interaction.  
The identified hit compounds were further 
investigated for their effects on a human pancreatic 
cancer cell model consisting of S100P-
overexpressing cells (BxPC-3) and/or cells 
expressing reduced amounts of S100P (Panc-1) 
using the MTS assay (CellTiter AQ, Promega, for 
metabolic activity), LDH release assay (CytoTox, 
Promega, for cell toxicity), and the Transwell cell 
invasion assay. 
RESULTS: BxPC-3 cells treated with hit 
compounds [3] for 48 hours, at 10µM, demonstrated 
a significant reduction (p<0.0001) in cell 
invasion; whereas no effect was observed for the 
Panc-1 cells suggesting a S100P-specific 
mechanism (Figure 1). MTS and LDH release 
assays revealed that the compounds did not exhibit 
general cytotoxicity over an extended period of 
time.  
 
Fig. 1: Transwell invasion assay of novel hit 
compounds. A) Invasion of BxPC-3 treated with 
lead compounds B) Data are mean ± SEM of two 
independent experiments. Statistical significance 
was assessed by one-way ANOVA and Dunnet’s 
posthoc test *p<0.0001 vs chemoattractant. 
DISCUSSION & CONCLUSIONS: Results from 
this project confirm that blocking the interaction 
between S100P and RAGE can suppress the 
migration, and invasion of carcinoma of the BxPC-
3 cell line which may provide a novel approach for 
treatment of pancreatic cancer. Further studies aim 
to investigate the effects of these lead compounds in 
angiogenesis and their effects on the expression of 
key cell signalling proteins in the development and 
progress of pancreatic cancer.  
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